4//SEC Filing
Sakiris Spiro Kevin 4
Accession 0001493152-23-024239
CIK 0001725430other
Filed
Jul 10, 8:00 PM ET
Accepted
Jul 11, 4:40 PM ET
Size
10.4 KB
Accession
0001493152-23-024239
Insider Transaction Report
Form 4
Sakiris Spiro Kevin
Chief Financial Officer
Transactions
- Conversion
Common Stock
2023-05-10$5.80/sh+2,399$13,914→ 4,745 total(indirect: Held by Anest Holdings) - Conversion
Series D Convertible Preferred Stock
2023-05-10−15,993→ 0 total(indirect: Held by Anest Holdings)→ Common Stock (2,399 underlying)
Holdings
- 3,765
Common Stock
Footnotes (4)
- [F1]On February 9, 2023, the Issuer effected a 1-for-20 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split. This Form 4 also corrects the number of securities held directly and indirectly by Mr. Sakiris. Prior to the Reverse Split, each share of Series D Convertible Preferred Stock (the "Preferred Stock") was convertible into 3 shares of common stock. Following the Reverse Split, each share of Preferred Stock was convertible into 0.15 shares of common stock.
- [F2]Following the Trigger Date (defined below), each share of Preferred Stock was convertible at any time at the option of the holder and without payment of further consideration. The Preferred Stock has no expiration date. The term "Trigger Date" means the earlier to occur of (i) the date that the last of (a) the shareholders approve conversion of the Preferred Stock or (b) the shareholders approve a reverse split of the Issuer's common stock; or (ii) the date which is 60 days following the date on which the common stock is no longer listed on the Nasdaq, the NYSE or the NYSE American. The Issuer's stockholders approved the conversion of the Preferred Stock at a meeting of stockholders on May 8, 2023, and effective as of May 10, 2023, all shares Preferred Stock were converted into common stock.
- [F3]On December 22, 2022, Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, purchased 15,993 units from the Issuer in a private placement. Each unit consists of one share of Series D Convertible Preferred Stock (valued at $0.87 each (pre- Reverse Split)) and three common stock purchase warrants (collectively valued at $0.35(pre- Reverse Split), or $0.1267 each (pre- Reverse Split)). The purchase price of each unit was $1.25 per unit (pre- Reverse Split).
- [F4]These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director.
Documents
Issuer
INTELLIGENT BIO SOLUTIONS INC.
CIK 0001725430
Entity typeother
Related Parties
1- filerCIK 0001830957
Filing Metadata
- Form type
- 4
- Filed
- Jul 10, 8:00 PM ET
- Accepted
- Jul 11, 4:40 PM ET
- Size
- 10.4 KB